Esticast Logo
Get In Touch!

Cancer Immunotherapy Global Market Report 2021 - COVID-19 Growth and Change

  • Published On: Mar, 2020
  • Category: Healthcare
  • Pages: 120
The global Cancer Immunotherapy market size is estimated at 157.91 billion USD with a CAGR of 9.9% during the forecasted period from 2021-2028.

Market Dynamics

The global Cancer Immunotherapy market size is estimated at 157.91 billion USD with a CAGR of 9.9% during the forecasted period from 2021-2028. The key factors that impel the growth of Cancer Immunotherapy market is attributed to the rising adoption of immunotherapy over conventional treatments. Also, factors such as ever-growing occurrence of cancer coupled with changing lifestyles is expected to fuel the market growth. Moreover, upswing in research & development activities coupled with new approvals is significantly impacting the market growth. In addition, rising investments for development & improvement of biosimilars and monoclonal antibodies is fostering the market size. On the other hand, high cost of cancer therapy can be a major factor to restrain the market growth. In addition, development of a new can be a complicated and time-consuming process along with lack of skilled professional which can hamper the Cancer Immunotherapy market growth. The surging incidence and prevalence rates of cancer coupled with increasing adoption of advanced cancer treatments is catalyzing the market growth. Prominent market players are researching diligently to develop new cancer treatment methods, which is thereby supporting the growth of the market. For instance, in November 2016, F. Hoffman La Roche launched a USD 100 million network of 21 academic research centers focused on cancer immunotherapy R&D. Further, a strong pipeline of immune-oncology drugs is expected to support market growth. Moreover, in recent years, the increasing shift from conventional chemotherapies to immunotherapies is boosting the overall market growth.

Market Segmentation      

The global cancer immunotherapy market has been segmented into cancer type and product type. The cancer type segment has been divided into breast cancer, melanoma, lung cancer, colorectal cancer, prostate cancer, ovarian cancer, head & neck, and pancreatic cancer. A number of immunotherapy drugs including few monoclonal antibodies are approved for the treatment of metastatic non-squamous non-small cell lung cancer (NSCLC). The use of cancer immunotherapies for melanoma is growing owing to the on-going development of new drugs and increasing R&D activities in this field. The product type segment has been divided into immunomodulators, monoclonal antibodies, and oncolytic viral therapies & cancer vaccines. The monoclonal antibodies segment is estimated to hold a substantial share in the market owing to the rising R&D investments in monoclonal antibodies.

Regional Analysis

Based on geography, North America held a major share in the global cancer immunotherapy market in the year 2019. The strong presence of companies such as Bayer AG, Novartis AG, Amgen Inc., AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, among others is supporting the market growth in the region. Further, a huge customer base coupled with favorable reimbursement policies is boosting the regional market. Moreover, an increasing number of hospitals and clinics and surging prevalence of various types of cancer is expected to enhance the market growth in the coming years. According to the data published by the American Cancer Society, about 1,762,450 new cancer cases were estimated to be diagnosed in 2019 in the U.S. The European region is anticipated to hold a second-largest share in the global cancer immunotherapy market. The growing number of cancer treatments in countries, such as the UK, France, Spain, Germany, and Italy, owing to increasing cancer prevalence is expected to increase market growth. Further, in the Asia Pacific region, the market growth is attributed to improving healthcare infrastructure, increasing government spending on healthcare especially in countries such as India and China, and the large presence of the target population.

Key Players

Some of the major companies operating in the global market include Amgen Inc., Bayer AG, Bristol-Myers Squibb, AstraZeneca, F. Hoffman La Roche, Eli Lilly and Co., Johnson & Johnson, Novartis, Merck and Co., and Pfizer. Cancer immunotherapy has become a crucial factor for revenue generation for companies like Bristol-Myers Squibb, Merck, and F. Hoffman La Roche.  Further, key players are engaged in growth strategies such as product launch, mergers and acquisitions, and partnerships.

Recent Development in the Market by Key Players:

  • In December 2019, F. Hoffman La Roche received the FDA approval for Tecentriq plus chemotherapy for the first-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC).
  • In December 2019, Johnson & Johnson acquired TARIS Biomedical LLC, a biotechnology company engaged in developing novel delivery systems for bladder diseases treatment including cancer.
  • In September 2017, Merck launched Keytruda (pembrolizumab), a blockbuster cancer drug in India. Keytruda addressed as a game-changer therapy in the field of oncology and is anticipated to facilitate the immune system to recognize and selectively fight only cancer cells instead of aggressively attacking cancer cells and endangering healthy cells in the process.

Cancer Immunotherapy Market Key Segments:

By Cancer Type
  • Breast Cancer
  • Melanoma
  • Lung Cancer
  • Colorectal cancer
  • Prostate Cancer
  • Ovarian cancer
  • Head & Neck
  • Pancreatic Cancer
By Product Type
  • Immunomodulators
  • Monoclonal Antibodies
  • Oncolytic Viral Therapies & Cancer Vaccines
By Geography
  • North America
    • U.S.
    • Canada
  • Europe
    • U.K
    • Germany
    • France
    • Italy
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Mexico
    • Rest of South America
  • Middle East & Africa
    • GCC Countries
    • Africa
    • Rest of Middle East & Africa
Frequently Asked Questions (FAQ): What is the market size of the global cancer immunotherapy market? -The market size of the global cancer immunotherapy market in 2019 was $59.2 billion. Who are the major companies operating in the global cancer immunotherapy market? - Prominent companies operating in the cancer immunotherapy market include Bayer AG, Bristol-Myers Squibb, AstraZeneca, Amgen Inc., F. Hoffman La Roche, Johnson & Johnson, Novartis, Merck and Co., Eli Lilly and Co., and Pfizer.

Table of Content 1. Market Introduction 1.1. Executive Summary 1.2. Market Definition 1.3. Market Scope 2. Research Methodology 2.1. Primary Research 2.2. Research Methodology 2.3. Assumptions & Exclusions 2.4. Secondary data sources 3. Global Cancer Immunotherapy Market Overview 3.1. Report Segmentation & Scope 3.2. Key Market Trend 3.3. Drivers 3.4. Restraints 3.5. Opportunities 3.6. Porter’s Five Forces Analysis 3.6.1. Bargaining Power of Supplier 3.6.2. Bargaining Power of Buyer 3.6.3. Threat of Substitute 3.6.4. Threat of New Entrants 3.6.5. Competitive Rivalry 3.7 PESTEL Analysis 3.7.1. Political Landscape 3.7.2. Economic Landscape 3.7.3. Technological Landscape 3.7.4. Environmental Landscape 3.7.5. Social Landscape 3.8. Market Share Analysis 4. Global Cancer Immunotherapy Market, By Cancer Type 4.1. Overview 4.2. Breast Cancer 4.2.1. Market Size & Forecast, 2019-2026 4.3. Melanoma 4.3.1. Market Size & Forecast, 2019-2026 4.4. Lung Cancer 4.4.1. Market Size & Forecast, 2019-2026 4.5. Colorectal Cancer 4.5.1. Market Size & Forecast, 2019-2026 4.6. Prostate Cancer 4.6.1. Market Size & Forecast, 2019-2026 4.7. Ovarian Cancer 4.7.1. Market Size & Forecast, 2019-2026 4.8. Head & Neck 4.8.1. Market Size & Forecast, 2019-2026 4.9. Pancreatic Cancer 4.9.1. Market Size & Forecast, 2019-2026 5. Global Cancer Immunotherapy Market, By Product Type 5.1. Overview 5.2. Immunomodulators 5.2.1. Market Size & Forecast, 2019-2026 5.3. Monoclonal Antibodies 5.3.1 Market Size & Forecast, 2019-2026 5.4. Oncolytic viral Therapies & Cancer Vaccines 5.4.1 Market Size & Forecast, 2019-2026 6. Global Cancer Immunotherapy Market, Region 6.1. Overview 6.1.1. Global Market Size & Forecast, 2019-2026 6.2. North America Cancer Immunotherapy Market 6.2.1. North America Market Size & Forecast, 2019-2026, By Country 6.2.2. North America Market Size & Forecast, 2019-2026, By Cancer Type 6.2.3. North America Market Size & Forecast, 2019-2026, By Product Type 6.2.4. U.S. 6.2.4.1. Market Size and Forecast, 2019-2026, By Cancer Type 6.2.4.2. Market Size and Forecast, 2019-2026, By Product Type 6.2.5. Canada 6.2.5.1. Market Size and Forecast, 2019-2026, By Cancer Type 6.2.5.2. Market Size and Forecast, 2019-2026, By Product Type 6.3. Europe Cancer Immunotherapy Market 6.3.1. Europe Market Size & Forecast, 2019-2026, By Country 6.3.2. Europe Market Size & Forecast, 2019-2026, By Cancer Type 6.3.3. Europe Market Size & Forecast, 2019-2026, By Product Type 6.3.4. Germany 6.3.4.1. Market Size and Forecast, 2019-2026, By Cancer Type 6.3.4.2. Market Size and Forecast, 2019-2026, By Product Type 6.3.5. France 6.3.5.1. Market Size and Forecast, 2019-2026, By Cancer Type 6.3.5.2. Market Size and Forecast, 2019-2026, By Product Type 6.3.6. UK 6.3.6.1. Market Size and Forecast, 2019-2026, By Cancer Type 6.3.6.2. Market Size and Forecast, 2019-2026, By Product Type 6.3.7. Italy 6.3.7.1. Market Size and Forecast, 2019-2026, By Cancer Type 6.3.7.2. Market Size and Forecast, 2019-2026, By Product Type 6.3.8. Spain 6.3.8.1. Market Size and Forecast, 2019-2026, By Cancer Type 6.3.8.2. Market Size and Forecast, 2019-2026, By Product Type 6.3.9. Rest of Europe 6.3.9.1. Market Size and Forecast, 2019-2026, By Cancer Type 6.3.9.2. Market Size and Forecast, 2019-2026, By Product Type 6.4. Asia-Pacific Cancer Immunotherapy Market 6.4.1. Asia-Pacific Market Size & Forecast, 2019-2026, By Country 6.4.2. Asia-Pacific Market Size & Forecast, 2019-2026, By Cancer Type 6.4.3. Asia-Pacific Market Size & Forecast, 2019-2026, By Product Type 6.4.4. Japan 6.4.4.1. Market Size and Forecast, 2019-2026, By Cancer Type 6.4.4.2. Market Size and Forecast, 2019-2026, By Product Type 6.4.5. China 6.4.5.1. Market Size and Forecast, 2019-2026, By Cancer Type 6.4.5.2. Market Size and Forecast, 2019-2026, By Product Type 6.4.6. Australia 6.4.6.1. Market Size and Forecast, 2019-2026, By Cancer Type 6.4.6.2. Market Size and Forecast, 2019-2026, By Product Type 6.4.7. India 6.4.7.1. Market Size and Forecast, 2019-2026, By Cancer Type 6.4.7.2. Market Size and Forecast, 2019-2026, By Product Type 6.4.8. South Korea 6.4.8.1. Market Size and Forecast, 2019-2026, By Cancer Type 6.4.8.2. Market Size and Forecast, 2019-2026, By Product Type 6.4.9. Rest of Asia-Pacific 6.4.9.1. Market Size and Forecast, 2019-2026, By Cancer Type 6.4.9.2. Market Size and Forecast, 2019-2026, By Product Type 6.5. South America Cancer Immunotherapy Market 6.5.1. South America Market Size & Forecast, 2019-2026, By Country 6.5.2. South America Market Size & Forecast, 2019-2026, By Cancer Type 6.5.3. South America Market Size & Forecast, 2019-2026, By Product Type 6.5.4. Brazil 6.5.4.1. Market Size and Forecast, 2019-2026, By Cancer Type 6.5.4.2. Market Size and Forecast, 2019-2026, By Product Type 6.5.5. Argentina 6.5.5.1. Market Size and Forecast, 2019-2026, By Cancer Type 6.5.5.2. Market Size and Forecast, 2019-2026, By Product Type 6.5.6. Rest of South America 6.5.6.1. Market Size and Forecast, 2019-2026, By Cancer Type 6.5.6.2. Market Size and Forecast, 2019-2026, By Product Type 6.6. Middle East & Africa Cancer Immunotherapy Market 6.6.1. Middle East & Africa Market Size & Forecast, 2019-2026, By Country 6.6.2. Middle East & Africa Market Size & Forecast, 2019-2026, By Cancer Type 6.6.3. Middle East & Africa Market Size & Forecast, 2019-2026, By Product Type 6.6.4. GCC Countries 6.6.4.1. Market Size and Forecast, 2019-2026, By Cancer Type 6.6.4.2. Market Size and Forecast, 2019-2026, By Product Type 6.6.5. Egypt 6.6.5.1. Market Size and Forecast, 2019-2026, By Cancer Type 6.6.5.2. Market Size and Forecast, 2019-2026, By Product Type 6.6.6. South Africa 6.6.6.1. Market Size and Forecast, 2019-2026, By Cancer Type 6.6.6.2. Market Size and Forecast, 2019-2026, By Product Type 6.6.7. Rest of Middle East & Africa 6.6.7.1. Market Size and Forecast, 2019-2026, By Cancer Type 6.6.7.2. Market Size and Forecast, 2019-2026, By Product Type 9. Company Profile 9.1. Bayer AG 9.1.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 9.1.2. Product Information, and Specification 9.1.3. Financial Performance 9.1.4. Strategic Initiatives 9.2. Bristol-Myers Squibb 9.3. AstraZeneca 9.4. Amgen Inc. 9.5. F. Hoffman La Roche 9.6 Johnson & Johnson 9.7 Novartis 9.8 Merck and Co. 9.9 Eli Lilly and Co. 9.10 Pfizer 10. List of Tables Table 1 Global Cancer Immunotherapy Market Share, By Cancer Type, 2016-2026 ($Billion) Table 2 Global Cancer Immunotherapy Market Share, By Product Type, 2016-2026 ($Billion) Table 3 Global Cancer Immunotherapy Market Value, 2016-2026 ($Billion) Table 4 North America, Cancer Immunotherapy Market Value and Growth Rate, 2016-2026 ($Billion) Table 5 North America, Cancer Immunotherapy Market Share Value, By Country, 2016-2026 ($Billion) Table 6 North America Cancer Immunotherapy Market Share Value, By Cancer Type, 2016-2026 ($Billion) Table 7 North America Cancer Immunotherapy Market Share Value, By Product Type 2016-2026 ($Billion) Table 8 U.S. Cancer Immunotherapy Market Share Value, By Cancer Type, 2016-2026 ($Billion) Table 9 U.S. Cancer Immunotherapy Market Share Value, By Product Type 2016-2026 ($Billion) Table 10 Canada Cancer Immunotherapy Market Share Value, By Cancer Type, 2016-2026 ($Billion) Table 11 Canada Cancer Immunotherapy Market Share Value, By Product Type 2016-2026 ($Billion) Table 12 Europe Cancer Immunotherapy Market Value and Growth Rate, 2016-2026 ($Billion) Table 13 Europe Cancer Immunotherapy Market Share Value, By Country, 2016-2026 ($Billion) Table 14 Europe Cancer Immunotherapy Market Share Value, By Cancer Type, 2016-2026 ($Billion) Table 15 Europe Cancer Immunotherapy Market Share Value, By Product Type, 2016-2026 ($Billion) Table 16 UK Cancer Immunotherapy Market Share Value, By Cancer Type, 2016-2026 ($Billion) Table 17 UK Cancer Immunotherapy Market Share Value, By Product Type, 2016-2026 ($Billion) Table 18 Germany Cancer Immunotherapy Market Share Value, By Cancer Type, 2016-2026 ($Billion) Table 19 Germany Cancer Immunotherapy Market Share Value, By Product Type, 2016-2026 ($Billion) Table 20 France Cancer Immunotherapy Market Share Value, By Cancer Type, 2016-2026 ($Billion) Table 21 France Cancer Immunotherapy Market Share Value, By Product Type, 2016-2026 ($Billion) Table 22 Italy Cancer Immunotherapy Market Share Value, By Cancer Type, 2016-2026 ($Billion) Table 23 Italy Cancer Immunotherapy Market Share Value, By Product Type, 2016-2026 ($Billion) Table 24 Rest of Europe Cancer Immunotherapy Market Share Value, By Cancer Type, 2016-2026 ($Billion) Table 25 Rest of Europe Cancer Immunotherapy Market Share Value, By Product Type, 2016-2026 ($Billion) Table 26 Asia Pacific Cancer Immunotherapy Market Value and Growth Rate, 2016-2026 ($Billion) Table 27 Asia Pacific Cancer Immunotherapy Market Share Value, By Country, 2016-2026 ($Billion) Table 28 Asia Pacific Cancer Immunotherapy Market Share Value, By Cancer Type, 2016-2026 ($Billion) Table 29 Asia Pacific Cancer Immunotherapy Market Share Value, By Product Type, 2016-2026 ($Billion) Table 30 India Cancer Immunotherapy Market Share Value, By Cancer Type, 2016-2026 ($Billion) Table 31 India Cancer Immunotherapy Market Share Value, By Product Type, 2016-2026 ($Billion) Table 32 China Cancer Immunotherapy Market Share Value, By Cancer Type, 2016-2026 ($Billion) Table 33 China Cancer Immunotherapy Market Share Value, By Product Type, 2016-2026 ($Billion) Table 34 Japan Cancer Immunotherapy Market Share Value, By Cancer Type, 2016-2026 ($Billion) Table 35 Japan Cancer Immunotherapy Market Share Value, By Product Type, 2016-2026 ($Billion) Table 36 South Korea Cancer Immunotherapy Market Share Value, By Cancer Type, 2016-2026 ($Billion) Table 37 South Korea Cancer Immunotherapy Market Share Value, By Product Type, 2016-2026 ($Billion) Table 38 Rest of Asia Pacific Cancer Immunotherapy Market Share Value, By Cancer Type, 2016-2026 ($Billion) Table 39 Rest of Asia Pacific Cancer Immunotherapy Market Share Value, By Product Type, 2016-2026 ($Billion) Table 40 South America Cancer Immunotherapy Market Value and Growth Rate, 2016-2026 ($Billion) Table 41 South America Cancer Immunotherapy Market Share Value, By Country, 2016-2026 ($Billion) Table 42 South America Cancer Immunotherapy Market Share Value, By Cancer Type, 2016-2026 ($Billion) Table 43 South America Cancer Immunotherapy Market Share Value, By Product Type, 2016-2026 ($Billion) Table 44 Brazil Cancer Immunotherapy Market Share Value, By Cancer Type, 2016-2026 ($Billion) Table 45 Brazil Cancer Immunotherapy Market Share Value, By Product Type, 2016-2026 ($Billion) Table 46 Argentina Cancer Immunotherapy Market Share Value, By Cancer Type, 2016-2026 ($Billion) Table 47 Argentina Cancer Immunotherapy Market Share Value, By Product Type, 2016-2026 ($Billion) Table 48 Mexico Cancer Immunotherapy Market Share Value, By Cancer Type, 2016-2026 ($Billion) Table 49 Mexico Cancer Immunotherapy Market Share Value, By Product Type, 2016-2026 ($Billion) Table 50 Rest of South America, Cancer Immunotherapy Market Share Value, By Cancer Type, 2016-2026 ($Billion) Table 51 Rest of South America Cancer Immunotherapy Market Share Value, By Product Type, 2016-2026 ($Billion) Table 52 Middle East & Africa Cancer Immunotherapy Market Value and Growth Rate, 2016-2026 ($Billion) Table 53 Middle East & Africa Cancer Immunotherapy Market Share Value, By Country, 2016-2026 ($Billion) Table 54 Middle East & Africa Cancer Immunotherapy Market Share Value, By Cancer Type, 2016-2026 ($Billion) Table 55 Middle East & Africa Cancer Immunotherapy Market Share Value, By Product Type, 2016-2026 ($Billion) Table 56 GCC Countries Cancer Immunotherapy Market Share Value, By Cancer Type, 2016-2026 ($Billion) Table 57 GCC Countries Cancer Immunotherapy Market Share Value, By Product Type, 2016-2026 ($Billion) Table 58 Africa Cancer Immunotherapy Market Share Value, By Cancer Type, 2016-2026 ($Billion) Table 59 Africa Cancer Immunotherapy Market Share Value, By Product Type, 2016-2026 ($Billion) Table 60 Rest of Middle East & Africa Cancer Immunotherapy Market Share Value, By Cancer Type, 2016-2026 ($Billion) Table 61 Rest of Middle East & Africa Cancer Immunotherapy Market Share Value, By Product Type, 2016-2026 ($Billion) Table 62 Recent Developments 10. List of Figures Figure 1 Global Cancer Immunotherapy Market Overview Figure 2 Global Cancer Immunotherapy Market Segmentation Figure 3 Global Cancer Immunotherapy Market Drivers Figure 4 Global Cancer Immunotherapy Market Restraints Figure 5 Global Cancer Immunotherapy Market Porter’s Analysis Figure 6 Global Cancer Immunotherapy Market share, By Cancer Type, 2018 VS 2026 (%) Figure 7 Global Cancer Immunotherapy Market share, By Product Type, 2018 VS 2026 (%) Figure 8 U.S. Cancer Immunotherapy Market share, 2016-2026 ($Billion) Figure 9 Canada Cancer Immunotherapy Market share, 2016-2026 ($Billion) Figure 10 U.K. Cancer Immunotherapy Market share, 2016-2026 ($Billion) Figure 11 Germany Cancer Immunotherapy Market share, 2016-2026 ($Billion) Figure 12 France Cancer Immunotherapy Market share, 2016-2026 ($Billion) Figure 13 Italy Cancer Immunotherapy Market share, 2016-2026 ($Billion) Figure 14 Rest of Europe Cancer Immunotherapy Market share, 2016-2026 ($Billion) Figure 15 India Cancer Immunotherapy Market share, 2016-2026 ($Billion) Figure 16 China Cancer Immunotherapy Market share, 2016-2026 ($Billion) Figure 17 Japan Cancer Immunotherapy Market share, 2016-2026 ($Billion) Figure 18 South Korea Cancer Immunotherapy Market share, 2016-2026 ($Billion) Figure 19 Rest of Asia Pacific Cancer Immunotherapy Market share, 2016-2026 ($Billion) Figure 20 Brazil Cancer Immunotherapy Market share, 2016-2026 ($Billion) Figure 21 Argentina Cancer Immunotherapy Market share, 2016-2026 ($Billion) Figure 22 Rest of South America Cancer Immunotherapy Market share, 2016-2026 ($Billion) Figure 23 GCC Countries Cancer Immunotherapy Market share, 2016-2026 ($Billion) Figure 24 Africa Cancer Immunotherapy Market share, 2016-2026 ($Billion) Figure 25 Rest of Middle East & Africa Cancer Immunotherapy Market share, 2016-2026 ($Billion)

  • Amgen Inc.
  • Bayer AG
  • Bristol-Myers Squibb
  • AstraZeneca
  • F. Hoffman La Roche
  • Eli Lilly and Co.
  • Johnson & Johnson
  • Novartis
  • Merck and Co.
  • Pfizer

Select License Type

  • $4700
  • $5600
  • $2000
  • Buy Now

Report Highlights:

Complete overview of market
Major drivers, restrain, opportunities, and challenges of the market
Market Trends and how they are boosting the market growth
Changing dynamics in the Market
Complete overview of the market
Historical, Base year, projected, and current market size in terms of value and volume
COVID-19 Impact analysis of the market
Current industry trends and developments

CLIENTS

Esticast Logo

CORPORATE OFFICE

location  (US)

1055 West 7th Street, Los Angeles, CA 90017 (P) US

phone  +1-213-262-0704
location  (APAC Address)

Office No. 407, Navale Icon IT Park, Near Navale Bridge, Narhe, Pune, Maharashtra 411041

phone  +91-959-503-5024

COMPANY

SECURE ONLINE PAYMENTS

  • visa
  • mastercard
  • amex
  • discover

FOLLOW US

  • facebook
  • linkedin
  • phone
  • youtube
© 2022 | All Rights Reserved by Esticast Research & Consulting